Regulatory
May 02, 2026
EU Annex 1 revision: what excipient suppliers need to demonstrate in 2026
How the revised contamination control strategy is reshaping supplier qualification for sterile-grade excipients.
Read articleInsights
Pharma market intelligence and regulatory updates
Practical analysis from our sourcing and regulatory teams — written for procurement leaders, QA heads, and supply chain managers.
Supply Chain
Apr 18, 2026
API price volatility Q2 2026 — paracetamol, metformin, statins
A category-by-category look at where pricing pressure is easing and where it isn't, with a 90-day outlook.
Read articleQuality
Apr 03, 2026
Nitrosamine impurities: a practical risk-assessment framework for procurement
Building a defensible position on nitrosamine risk before your QA team asks for one.
Read articleMarkets
Mar 21, 2026
India's PLI scheme three years in: which intermediates are now competitive at scale
We mapped 60 intermediate molecules to identify where Indian capacity has truly caught up to Chinese pricing.
Read articleRegulatory
Mar 07, 2026
USP-NF excipient performance tests: keeping your filings current
Recent USP general chapter updates that quietly affect tablet manufacturers.
Read articleSustainability
Feb 19, 2026
Green chemistry credits in API procurement RFPs: a buyer's guide
How to evaluate sustainability claims from API manufacturers without falling for greenwash.
Read article